DeepCure, which is developing a renal denervation (RDN) medical device, said on the 8th that it has brought on Raymond Townsend, emeritus professor at the Perelman School of Medicine at the University of Pennsylvania and a leading global authority in hypertension, as an adviser.
Professor Townsend is an internationally recognized scholar in hypertension research, was selected as the American Heart Association (AHA) Physician of the Year in 2016, and is a Fellow of the AHA.
Townsend served as principal investigator for SPYRAL HTN, Medtronic's large-scale global clinical program for RDN devices, playing a key role in demonstrating the clinical efficacy of RDN therapy. In addition, he served as vice chair of the writing committee for the American Heart Association's 2024 scientific statement on renal denervation for the treatment of hypertension, helping lead the establishment of related global guidelines.
A DeepCure official said, "Professor Townsend's addition recognizes the global potential of the company's technology," and added, "Based on his expert advice, we will improve the completeness of the key clinical trial we are preparing in the United States."
With this appointment, DeepCure plans to expand its global network and move forward in earnest with the key clinical procedures for U.S. Food and Drug Administration approval and commercialization of its in-house developed RDN device HyperQure™.